These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39161804)

  • 1. The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference.
    Kahr Rasmussen N; Berg B; Christiansen ASL; Neergaard JS; Ter-Borch G; Hildebrand EA; Gonczi M; Sparre T
    Patient Prefer Adherence; 2024; 18():1713-1727. PubMed ID: 39161804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study.
    Tran H; von Mackensen S; Abraham A; Castaman G; Hampton K; Knoebl P; Linari S; Odgaard-Jensen J; Neergaard JS; Stasyshyn O; Thaung Zaw JJ; Zulfikar B; Shapiro A
    Res Pract Thromb Haemost; 2024 May; 8(4):102476. PubMed ID: 39099801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
    Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
    Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.
    Shapiro AD; Angchaisuksiri P; Astermark J; Benson G; Castaman G; Chowdary P; Eichler H; Jiménez-Yuste V; Kavakli K; Matsushita T; Poulsen LH; Wheeler AP; Young G; Zupancic-Salek S; Oldenburg J
    Blood; 2019 Nov; 134(22):1973-1982. PubMed ID: 31444162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the usability and safety of the semaglutide single-dose pen-injectors through summative (human factors) usability testing.
    Klonoff DC; Bassock S; Dwyer A; Engels E; Qvist M; Sparre T; Snitker S
    J Diabetes Investig; 2021 Jun; 12(6):978-987. PubMed ID: 33034163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
    Matsushita T; Shapiro A; Abraham A; Angchaisuksiri P; Castaman G; Cepo K; d'Oiron R; Frei-Jones M; Goh AS; Haaning J; Hald Jacobsen S; Mahlangu J; Mathias M; Nogami K; Skovgaard Rasmussen J; Stasyshyn O; Tran H; Vilchevska K; Villarreal Martinez L; Windyga J; You CW; Zozulya N; Zulfikar B; Jiménez-Yuste V;
    N Engl J Med; 2023 Aug; 389(9):783-794. PubMed ID: 37646676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
    Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
    J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usability of devices for self-injection: results of a formative study on a new disposable pen injector.
    Lange J; Richard P; Bradley N
    Med Devices (Auckl); 2014; 7():195-203. PubMed ID: 24966698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A redesigned follitropin alfa pen injector for infertility: results of a market research study.
    Abbotts C; Salgado-Braga C; Audibert-Gros C
    Patient Prefer Adherence; 2011; 5():315-31. PubMed ID: 21792303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes.
    Warren ML; Brod M; Håkan-Bloch J; Sparre T; Chaykin LB
    Curr Med Res Opin; 2019 Sep; 35(9):1623-1629. PubMed ID: 30974973
    [No Abstract]   [Full Text] [Related]  

  • 12. Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.
    Fujioka K; Sparre T; Sun LY; Krogsgaard S; Kushner RF
    J Diabetes Sci Technol; 2015 Jul; 10(1):164-74. PubMed ID: 26183599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels.
    Roth EM; Bujas-Bobanovic M; Louie MJ; Cariou B
    Clin Ther; 2015 Sep; 37(9):1945-1954.e6. PubMed ID: 26278513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
    Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
    Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism.
    Zijlstra E; Coester HV; Heise T; Plum-Mörschel L; Rasmussen O; Rikte T; Pedersen LK; Qvist M; Sparre T
    Diabetes Obes Metab; 2018 May; 20(5):1140-1147. PubMed ID: 29369493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formative usability evaluation of a fixed-dose pen-injector platform device.
    Lange J; Nemeth T
    Med Devices (Auckl); 2018; 11():105-112. PubMed ID: 29670411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses.
    Longobardi S; Seidler A; Martins J; Beckers F; MacGillivray W; D'Hooghe T
    Expert Opin Drug Deliv; 2019 Sep; 16(9):1003-1014. PubMed ID: 31411099
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
    Chowdary P; Lethagen S; Friedrich U; Brand B; Hay C; Abdul Karim F; Klamroth R; Knoebl P; Laffan M; Mahlangu J; Miesbach W; Dalsgaard Nielsen J; Martín-Salces M; Angchaisuksiri P
    J Thromb Haemost; 2015 May; 13(5):743-54. PubMed ID: 25641556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.
    Yale JF; Roborel de Climens A; Aggarwal N; Dex T; Gerstein HC; Harris S; Hramiak I; Stewart J; Leiter LA
    Diabetes Ther; 2023 Feb; 14(2):377-386. PubMed ID: 36574199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.
    Shapiro AD; Angchaisuksiri P; Astermark J; Benson G; Castaman G; Eichler H; Jiménez-Yuste V; Kavakli K; Matsushita T; Poulsen LH; Wheeler AP; Young G; Zupančić-Šalek S; Oldenburg J; Chowdary P
    Blood Adv; 2022 Jun; 6(11):3422-3432. PubMed ID: 35290453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.